New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
17:46 EDTLNKD, ESRX, DISH, TGTSoros liquidates stakes in LinkedIn, Express Scripts, DISH, Target over quarter
News For LNKD;ESRX;DISH;TGT From The Last 14 Days
Check below for free stories on LNKD;ESRX;DISH;TGT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 19, 2014
18:41 EDTESRXExpress Scripts awarded 7-year TRICARE Pharmacy Program contract
Subscribe for More Information
April 18, 2014
09:47 EDTLNKDLinkedIn announces 300M members reached worldwide
Subscribe for More Information
April 15, 2014
10:20 EDTDISHDirecTV to stop carrying WWE pay-per-views, PWTorch says
Subscribe for More Information
April 14, 2014
10:02 EDTLNKDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:42 EDTLNKDLinkedIn initiated with an Overweight at Atlantic Equities
Atlantic Equities believes the recent pullback in shares of LinkedIn has created an attractive entry point. The firm started shares with an Overweight rating and $240 price target.
06:53 EDTTGTTarget breach sparks retail push to upgrade card technology, Bloomberg says
Subscribe for More Information
April 11, 2014
08:00 EDTLNKDLinkedIn remains a favorite large cap name at Piper Jaffray
Piper Jaffray says LinkedIn remains one of its favorite long-term large cap names. The firm believes investors are overlooking two new opportunities for the company: the addition of Sales Solutions and the Ad API. Piper reiterates an Overweight rating on LinkedIn with a $270 price target.
07:26 EDTDISHTime Warner struggling to force Dodgers network on pay-TV players, LAT say
Subscribe for More Information
06:47 EDTLNKDSamsung ups S5 incentives to fend off rivals, Bloomberg says
Subscribe for More Information
April 10, 2014
10:44 EDTLNKDStocks with call strike movement; FSLR LNKD
Subscribe for More Information
April 9, 2014
11:43 EDTESRXGilead defended by analysts after recent pullback
Subscribe for More Information
10:06 EDTLNKDOn The Fly: Analyst Upgrade Summary
AmSurg (AMSG) upgraded to Buy from Hold at Cantor... CBOE Holdings (CBOE) upgraded to Buy from Neutral at BofA/Merrill... Carlyle Group (CG) upgraded to Outperform from Perform at Oppenheimer... FireEye (FEYE) upgraded to Buy from Hold at Topeka... Fortune Brands (FBHS) upgraded to Outperform from Neutral at Credit Suisse... Gray Television (GTN) upgraded to Outperform from Market Perform at Wells Fargo... Hibbett Sports (HIBB) upgraded to Overweight from Neutral at Piper Jaffray... LinkedIn (LNKD) upgraded to Buy from Hold at Topeka... Mallinckrodt (MNK) upgraded to Buy from Neutral at UBS... NXP Semiconductors (NXPI) upgraded to Strong Buy from Outperform at Raymond James... Nexstar (NXST) upgraded to Outperform from Market Perform at Wells Fargo... Penn National (PENN) upgraded to Overweight from Equalweight at Barclays... Philip Morris (PM) upgraded to Neutral from Reduce at Nomura... SAIC (SAIC) upgraded to Market Perform from Underperform at Wells Fargo... Sinclair Broadcast (SBGI) upgraded to Outperform from Market Perform at Wells Fargo... Yelp (YELP) upgraded to Buy from Fair Value at CRT Capital... Danaher (DHR) upgraded to Strong Buy from Buy at ISI Group... Quanex (NX) upgraded at BB&T... Omnicell (OMCL) upgraded at Craig-Hallum... Volkswagen (VLKAY) upgraded to Outperform from Market Perform at Bernstein... Magna (MGA) upgraded to Neutral from Sell at Citigroup... Actavis (ACT) upgraded to Positive from Neutral at Susquehanna... E-Trade (ETFC) upgraded to Neutral from Underperform at BofA/Merrill... AmerisourceBergen (ABC) upgraded to Outperform from Market Perform at FBR Capital... CONSOL (CNX) upgraded to Outperform from Neutral at Macquarie.
09:36 EDTLNKDActive equity options trading on open
Subscribe for More Information
09:11 EDTLNKDOn The Fly: Pre-market Movers
Subscribe for More Information
08:41 EDTESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
06:33 EDTLNKDLinkedIn upgraded to Buy from Hold at Topeka
Subscribe for More Information
April 8, 2014
16:21 EDTLNKDOn The Fly: Closing Wrap
Subscribe for More Information
April 7, 2014
15:16 EDTLNKDLinkedin May volatility elevated as shares trend to 13-month low
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use